Serum-free, GMP Produced Medium
The Next Step Towards Scaling up Your Cell Therapy

Hematopoietic cells are commonly used in cell and gene therapy applications. During cell and gene therapy, blood cells are taken from the body, treated in the laboratory, and then returned to the patient. For these treatments, the safety and consistency of the cell culture medium is vital. It is desirable to obtain a high yield of viable cells within a short time with minimal scale up time required.

In order to support these requirements, Lonza has developed the TheraPEAK^® X-VIVO^® Media range of products. TheraPEAK^® X-VIVO^® Media is a GMP produced, high performing media series providing nutritionally adequate and balanced environments for a variety of hematopoietic cells, including T cells, NK cells, dendritic cells and more. Our scalable medium is widely cited in scientific publications and proven to reliably work in many cell therapy applications around the world, from research stages, to clinical trials, to FDA-approved cell therapies.

New Case Study: Access or download the file on the right side and learn how the X-VIVO^® Medium can help you improve the expansion of patients' T cells.

Discover our TheraPEAK^® X-VIVO^® Media and discuss with our experts how it can help you to take the next step in scaling up your cell therapy applications.

Features and Benefits of TheraPEAK^® X-VIVO^® Media

• Reduced variables with serum-free formulation
• Produced according to GMP guidelines ensuring safe insertion to clinical processes
• Multiple formulations allowing seemless transition into customer specific processes
• Custom packaging available to meet scale up needs
• Easy-to-use formulation only requiring addition of cytokines
• All formulations are devoid of antibiotics and phenol red

Find the Right Formulation for Your Cells

• TheraPEAK^® X-VIVO^® 10 Media are  optimized for slower growing, less mature cells, such as hematopoietic stem cells
• TheraPEAK^® X-VIVO^® 15 Media are most appropriate for rapidly growing cells, specifically cells of the immune system
• TheraPEAK^® X-VIVO^® 10 Media and 15 Media are also available with recombinant transferrin instead of native human transferrin

Find your medium of interest in the table below. Click on the catalog number to learn more or to place an order online.

Customization of packaging for specific applications is available. In addition to our GMP produced TheraPEAK^® X-VIVO^® Media, we also provide an extensive portfolio of research use only (RUO) formulations, such as the X-VIVO^® 20 Medium that has shown success in culturing rapidly growing cells, e.g. PBMCs. You may as well be interested in our large inventory of ready-to-ship, cryopreserved blood and immune cells including PBMCs, T cells, NK cells, dendritic cells and more. 

Selected References

Brentjens, R. J., Riviere, I., Park, J. H., Davila, M. L., Wang, X., Stefanski, J., Sadelain, M. (2011): Safety and persistence of adoptively transferred autologous CD19-targeted T cells in patients with relapsed or chemotherapy refractory B-cell leukemias. Blood, 118(18), 4817-4828. doi:10.1182/blood-2011-04-348540 

Moon, E. K., Carpenito, C., Sun, J., Wang, L. S., Kapoor, V., Predina, J., Albelda, S. M.: (2011): Expression of a Functional CCR2 Receptor Enhances Tumor Localization and Tumor Eradication by Retargeted Human T cells Expressing a Mesothelin-Specific Chimeric Antibody Receptor. Clinical Cancer Research,17(14), 4719-4730. doi:10.1158/1078-0432.ccr-11-0351 

Schalkwyk, M. C., Papa, S. E., Jeannon, J., Urbano, T. G., Spicer, J. F., & Maher, J. (2013): Design of a Phase I Clinical Trial to Evaluate Intratumoral Delivery of ErbB-Targeted Chimeric Antigen Receptor T-Cells in Locally Advanced or Recurrent Head and Neck Cancer. Human Gene Therapy Clinical Development,24(3), 134-142. doi:10.1089/humc.2013.144 

Singh, H., Figliola, M. J., Dawson, M. J., Olivares, S., Zhang, L., Yang, G., Cooper, L. J. (2013): Manufacture of Clinical-Grade CD19-Specific T Cells Stably Expressing Chimeric Antigen Receptor Using Sleeping Beauty System and Artificial Antigen Presenting Cells. PLoS ONE, 8(5). doi:10.1371/journal.pone.0064138

Discover our TheraPEAK^® X-VIVO^® Media and discuss with our experts how it can help you to take the next step in scaling up your cell therapy applications.